Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer s Disease Like Tau Aggregation

Similar documents
SUPPLEMENTARY INFORMATION

Nature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.

Supplementary Figure 1

Supporting Information. Post translational Modifications of Serotonin Type 4 Receptor Heterologously Expressed in. Mouse Rod Cells

Supplementary Figure 1. NAFL enhanced immunity of other vaccines (a) An over-the-counter, hand-held non-ablative fractional laser (NAFL).

Supporting Information

Supplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration

Nature Neuroscience: doi: /nn.2275

SUPPLEMENTARY MATERIAL

Supplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation.

A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design

Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood

W/T Itgam -/- F4/80 CD115. F4/80 hi CD115 + F4/80 + CD115 +

Supplementary Materials for

Zhu et al, page 1. Supplementary Figures

Soluble phospho-tau from Alzheimer's disease hippocampus drives. Elisabeth Sanchez-Mejias1,4*, Victoria Navarro2,3,4*, Sebastian Jimenez2,3,4,

Supplementary Material to Manuscript SREP A

SUPPLEMENTARY INFORMATION

Nature Medicine: doi: /nm.4322

Erbb2 transgenic mice: a tool to evaluate the potential efficacy of vaccination in the prevention and cure of carcinomas

1.0. FSL NMDAR-fEPSP 0.8. amplitude (mv) Intensity (µa) 2.0 SD FSL Time (ms)

Disrupting GluA2-GAPDH Interaction Affects Axon and Dendrite Development

Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2

Predictive PP1Ca binding region in BIG3 : 1,228 1,232aa (-KAVSF-) HEK293T cells *** *** *** KPL-3C cells - E E2 treatment time (h)

Pearson r = P (one-tailed) = n = 9

Supplementary Table 1

Supplementary material. VAMP7 controls T cell activation by regulating recruitment and phosphorylation of vesicular

Supplementary Materials for

Supplementary Materials

SUPPLEMENTARY INFORMATION

Supplementary Figure 1.

Effec<ve Use of PI3K and MEK Inhibitors to Treat Mutant K Ras G12D and PIK3CA H1047R Murine Lung Cancers

SUPPLEMENTARY FIGURES

Spleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.

Antibody H6-11 for Prostate Cancer Imaging

Supplementary Figures

LPS CD40 + IL-4. Vorinostat (24 Hours) Vorinostat (24 Hours) Panobinostat (24 Hours) Panobinostat (24 Hours) Romidepsin (48 Hours)

Supplemental Figure 1. Western blot analysis indicated that MIF was detected in the fractions of

Supporting Information Table of Contents

Nature Neuroscience: doi: /nn Supplementary Figure 1. Large-scale calcium imaging in vivo.

Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy

Inhibition of DYRK1A stimulates human beta-cell proliferation

Title: Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events

Comparison of open chromatin regions between dentate granule cells and other tissues and neural cell types.

activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows

Supplementary Figure 1 CD4 + T cells from PKC-θ null mice are defective in NF-κB activation during T cell receptor signaling. CD4 + T cells were

Nature Immunology: doi: /ni eee Supplementary Figure 1

Atg5 flox/flox ; CAG-Cre, 19M brain heart lung. spleen stomach colon. Takamura_Fig. S1

Supporting Information

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained

marker. DAPI labels nuclei. Flies were 20 days old. Scale bar is 5 µm. Ctrl is

SUPPLEMENTARY INFORMATION

The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy

Control GST GST-RAP. α2-mg. 170 kda. b-actin. 42 kda LRP-1

Supplementary Fig. 1: TBR2+ cells in different brain regions.

Supplementary Figure 1. ACE robotic platform. A. Overview of the rig setup showing major hardware components of ACE (Automatic single Cell

Supplementary Results: Age Differences in Participants Matched on Performance

a 10 4 Link et al. Supplementary Figure 1 Nature Immunology: doi: /ni.1842 Cells per mouse ( 10 5 ) TRPV2KO anti-gr1 anti-gr anti-f4/80

SUPPLEMENTARY INFORMATION

Neuronal Plasticity, Learning and Memory. David Keays Institute of Molecular Pathology

Supplementary Figure 1. ETBF activate Stat3 in B6 and Min mice colons

Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited

Supplementary Figure 1: Characterisation of phospho-fgfr-y463 antibody. (A)

Hippocampal protein kinase C signaling mediates the short-term memory

and follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the

Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines

hexahistidine tagged GRP78 devoid of the KDEL motif (GRP78-His) on SDS-PAGE. This

Novel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease

Supplementary Figure 1

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Nature Biotechnology: doi: /nbt Supplementary Figure 1

Supporting information

Targeting the p75 Receptor to Inhibit Degenerative Signaling and Tau Phosphorylation/Misfolding/ Missorting: Preclinical through Phase 1

Short- and long-lasting consequences of in vivo nicotine treatment

CD31 5'-AGA GAC GGT CTT GTC GCA GT-3' 5 ' -TAC TGG GCT TCG AGA GCA GT-3'

GANGLIOSIDES for Neuroscience Research

Structural basis for the role of inhibition in facilitating adult brain plasticity

Role of Tyk-2 in Th9 and Th17 cells in allergic asthma

More dendritic spines, changes in shapes of dendritic spines More NT released by presynaptic membrane

ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2

Suppl Video: Tumor cells (green) and monocytes (white) are seeded on a confluent endothelial

The Effects of Chemotherapy on Cognitive Behavior and Neurogenesis in an Animal Model of Pre- and Post- Menopausal Females

Endogenous TNFα orchestrates the trafficking of neutrophils into and within lymphatic vessels during acute inflammation

Suppl. Information Supplementary Figure 1. Strategy/latency analysis of individual mice during maze learning. a,

Supplementary information:

Supplementary Materials for

Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury

SD-1 SD-1: Cathepsin B levels in TNF treated hch

Mouse Anti-OVA IgM Antibody Assay Kit

Supplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation

Supplementary Figure 1. Properties of various IZUMO1 monoclonal antibodies and behavior of SPACA6. (a) (b) (c) (d) (e) (f) (g) .

Supplementary Materials for

COGNITIVE SCIENCE 107A. Hippocampus. Jaime A. Pineda, Ph.D.

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

SUPPLEMENTARY FIG. S2. Representative counting fields used in quantification of the in vitro neural differentiation of pattern of dnscs.

Supplementary Figure 1 IMQ-Induced Mouse Model of Psoriasis. IMQ cream was

Dual Tagging As an Approach to Isolate Endogenous Chromatin. Remodeling Complexes from Saccharomyces Cerevisiae

Supplementary Fig. 1

Danish Research Institute of Translational Neuroscience DANDRITE, Nordic-EMBL Partnership

Transcription:

, 1-11 manuscripts; doi:10.3390/vaccines20x000x Article OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer s Disease Like Tau Aggregation Monique Richter 1,2, Agneta Mewes 1,2, Manuela Fritsch 1,2, Ute Krügel 3, Ralf Hoffmann 1,2 and David Singer 1,2, * 1 2 3 Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Universität Leipzig, Leipzig 04103, Germany Center for Biotechnology and Biomedicine (BBZ), Universität Leipzig, Leipzig 04103, Germany Rudolf Boehm Institute for Pharmacology and Toxicology, Universität Leipzig, Leipzig 04107, Germany Supplementary Files Content Figure S1. Illustration of hippocampal regions quantified after immunohistochemistry using phosphorylation-dependent antibodies. Figure S2. Representative immunoblots of brain homogenates of P301S mice for analysis of total tau and phospho-tau. Total tau was stained by mab Tau5 and phospho-tau with mabs AT8, AT100 and AT180. Table S1. IgG titers of mice immunized with Tau 199 208 [ps202/pt205], (BT = behavioral test, x =no blood sample available, IR = immune response). Table S2. IgG titers of mice immunized with Tau 209 217 [pt212/ps214], (BT = behavioral test, x =no blood sample available, IR = immune response). Table S3. IgG titers of mice immunized with Tau 229 237 [pt231/ps235], (BT = behavioral test, x =no blood sample available, IR = immune response). Table S4. IgG 1/2a/2b/2c titers of mice immunized with Tau 199 208 [ps202/pt205]. Table S5. IgG 1/2a/2b/2c titers of mice immunized with Tau 209 217 [pt212/ps214]. Table S6. IgG 1/2a/2b/2c titers of mice immunized with Tau 229 237 [pt231/ps235].

S2 Figure S1. Illustration of hippocampal regions quantified after immunohistochemistry using phosphorylation-dependent antibodies. Exemplarily shown is the hippocampal formation of an untreated P301S mouse (48 weeks of age) using mab AT8 (Tau[pS202/pT205]). Within the hippocampal formation, the pyramidal cell layer of region CA1 (blue), CA2/3/4 (black) and the granular cell layer of the dentate gyrus (red, DG) are marked (left). In the indicated areas cells positively stained for phospho-tau were counted as exemplified in the magnified picture (right). Figure S2. Representative immunoblots of brain homogenates of P301S mice for analysis of total tau and phospho-tau. Total tau was stained by mab Tau5 and phospho-tau with mabs AT8, AT100 and AT180. Samples S1 S3: mice immunized with Tau 209 217 [pt212/ps214], S4 S10: mice immunized with Tau 229 237 [pt231/ps235] and S11 S13: placebo-treated P301S mice. As reference (Ref) an untreated P301S mouse was included. Soybean trypsin inhibitor (SBTI) was used as external standard.

S3 Table S1. IgG titers of mice immunized with Tau 199 208 [ps202/pt205], (BT = behavioral test, x = no blood sample available, IR = immune response). Mouse number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month final Weeks after immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of mice (weeks) 10 11 13 27 21 25 29 33/37 41/45 48 306 0 100 100,000 100,000 100,000 10,000 10,000 1000 1000 1000 309 0 100 100,000 100,000 100,000 10,000 1000 1000 1000 1000 312 0 100 100,000 100,000 100,000 10,000 10,000 1000 1000 100 316 0 10,000 100,000 10,0000 10,000 1000 1000 1000 1000 1000 320 0 1000 100,000 100,000 100,000 10,000 10,000 1000 1000 1000 360 0 1000 100,000 100,000 BT 100,000 10,000 10,000 10,000 10,000 361 0 100 10,000 10,000 BT 10,000 1000 x x x 362 0 100 10,000 1000 1000 1000 1000 1000 10000 1000 363 0 1000 10,000 10,000 BT 1000 1000 1000 1000 100 364 0 0 100,000 100,000 BT 100,000 10,000 10,000 10,000 1000 507 0 0 0 0 0 0 0 0 x 0 540 0 0 0 0 100 1000 100 0 0 0 541 0 0 0 0 0 0 0 0 0 0 558 0 100 10,000 1000 1000 0 0 100 1000 100 559 0 0 0 0 0 0 0 0 0 0 627 0 100 10,000 10,000 10,000 100,000 1000 1000 100 1000 628 0 100 10,000 10,000 10,000 10,000 10,000 1000 1000 1000 630 0 1000 100,000 100,000 100,000 100,000 100,000 10,000 10,000 10,000 634 x 100 0 0 0 0 0 0 0 0 626 0 1000 10,000 10,000 1000 10,000 1000 1000 776 0 0 10,000 100,000 100,000 10,000 10,000 10,000 794 0 0 100,000 100,000 100,000 100,000 10,000 10,000 812 0 0 100,000 10,000 100,000 10,000 10,000 10,000 838 0 0 0 100 10000 1000 0 1000 845 0 0 0 0 0 0 0 0 850 0 0 10,000 1000 1000 1000 100 1000

S4 Table S1. Cont. Mouse Number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month Final Weeks after Immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of Mice (Weeks) 10 11 13 27 21 25 29 33/37 41/45 48 851 0 0 0 0 100 0 0 0 858 0 0 0 0 0 0 1000 0 859 0 0 100,000 10,000 100,000 10,000 10,000 10,000 860 0 0 0 0 0 0 0 0 876 0 0 10,000 10,0000 10,000 10,000 10,000 879 0 0 10,000 100,000 10,000 10,000 10,000 933 0 0 100 1000 1000 1000 100 1037 0 0 0 0 0 100 0 1040 0 0 0 0 0 0 0 1041 0 0 0 0 0 0 0 1049 0 0 10,000 10,000 10,000 10,000 1000 1051 0 0 100 100 100 100 100 1052 0 0 0 0 0 0 0 1054 0 0 0 0 0 0 0 Total number of mice n = 39 n = 40 n = 40 n = 40 n = 36 n = 40 n = 40 n = 28 n = 17 n = 19 Total number of mice with IR n = 0 n = 15 n = 25 n = 26 n = 24 n = 27 n = 26 n = 19 n = 13 n = 14 [%] of mice with IR 0% 37.5% 62.5% 65% 66.7% 67.5% 65% 67.8% 76.5% 73.7%

S5 Table S2. IgG titers of mice immunized with Tau 209-217 [pt212/ps214], (BT = behavioral test, x = no blood sample available, IR = immune response). Mouse Number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month Final Weeks after Immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of Mice (Weeks) 10 11 13 27 21 25 29 33/37 41/45 48 289 0 100 10,000 100,000 10,000 10,000 1000 1000 1000 1000 291 0 100 10,000 100,000 1000 1000 1000 1000 1000 1000 295 100 0 10,000 100,000 10,000 10,000 10,000 1000 100 100 300 0 1000 10,000 10,000 1000 x x x x x 302 0 0 100,000 100,000 100,000 10,000 10,000 x x 1000 389 0 0 1000 100 0 0 0 0 0 0 390 0 0 100 10,000 BT 1000 100 100 100 100 391 0 0 1000 1000 1000 100 100 1000 100 100 392 0 0 1000 10,000 BT 10,000 1000 1000 1000 1000 394 0 100 1000 1000 1000 1000 10000 1000 100 100 498 0 0 1000 1000,000 1000,000 10,000 10,000 1000 x 1000 499 0 0 10,000 100,000 10,000 10,000 10,000 1000 10,000 1000 500 0 100 10,000 100,000 100,000 100,00 10,000 10,000 x 1000 537 0 100 100,000 100,000 100,000 10,000 10,000 10,000 1000 10,000 547 0 0 10,000 10,000 10,000 10,000 10,000 10,000 1000 1000 594 0 0 100 1000 x 100 100 0 0 0 596 0 0 0 1000 x 10,000 1000 100 100 100 597 0 100 0 100 x 1000 1000 100 100 100 603 0 100 10,000 1000 1000 1000 1000 100 100 100 605 0 0 0 1000 10,000 1000 10,000 0 1000 100 746 100 100 1000 10,000 10,000 10,000 1000 1000 748 0 0 10,000 10,000 1000 1000 1000 1000 753 0 0 1000 1000 1000 1000 100 100 760 0 0 0 10,000 1000 10,000 1000 1000 764 0 0 0 100 1000 1000 1000 1000 765 0 0 100 100 1000 1000 100 100

S6 Table S2. Cont. Mouse Number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month Final Weeks after Immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of Mice (Weeks) 10 11 13 27 21 25 29 33/37 41/45 48 766 0 0 1000 1000 1000 10,000 10,000 1000 813 0 0 100 1000 1000 1000 1000 1000 814 0 0 1000 1000 1000 1000 100 x 815 0 0 1000 10,0000 10,0000 10,000 10,000 10,000 936 0 0 1000 10,000 10,000 1000 1000 949 0 0 1000 100,000 100,000 10,000 10,000 951 0 0 1000 100,000 100,000 10,000 100,000 988 0 0 1000 10,000 10,000 1000 10,000 1003 0 0 100 10,000 1000 1000 1000 1004 0 0 100 10,000 10,000 10,000 10,000 1005 0 0 100 1000 1000 1000 x 1019 0 0 100 10,000 10,000 1000 1000 1020 0 0 1000 10,000 10,000 10,000 10,000 1022 0 0 10,000 10,000 10,000 10,000 10,000 Total number of mice n = 40 n = 40 n = 40 n = 40 n = 35 n = 39 n = 38 n = 27 n = 16 n = 19 Total number of mice with IR n = 2 n = 9 n = 35 n = 40 n = 34 n = 38 n = 37 n = 24 n = 14 n = 17 [%] of mice with IR 5% 22.5% 77.8% 100% 97.1% 97.4% 97.4% 88.9% 87.5% 89.5%

S7 Table S3. IgG titers of mice immunized with Tau 229-237 [pt231/ps235], (BT = behavioral test, x =no blood sample available, IR = immune response). Mouse Number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month Final Weeks after Immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of Mice (Weeks) 10 11 13 27 21 25 29 33/37 41/45 48 275 0 100 100,000 100,000 100,000 10,000 10,000 1000 1000 1000 280 100 100 100,000 100,000 100,000 100,000 10,000 10,000 1000 100 282 0 100 10,000 10,000 10,000 1000 0 1000 1000 1000 283 0 100 10000 10000 10000 1000 1000 100 0 1000 278 0 100 100,000 100,000 100,000 10,000 x x x 10,000 375 0 1000 10,000 100,000 BT 10,000 1000 100 100 1000 383 0 1000 1000 10,000 BT 1000 10,000 1000 100 100 424 0 1000 100,000 100,000 BT 100,000 100,000 100,000 10,000 1000 451 0 1000 10,000 10,000 BT 10,000 10,000 10,000 10,000 1000 452 0 100 100,000 100,000 BT 1000 1000 1000 1000 10,000 455 100 100 100,000 100,000 100,000 10,000 10,000 10,000 10,000 10,000 456 100 100 100,000 100,000 100,000 10,000 10,000 10,000 10,000 10,000 481 0 100 100,000 100,000 10,000 10,000 10,000 1000 1000 1000 506 100 100 10,000 100,000 10,000 1000 1000 1000 1000 1000 511 100 0 100,000 100,000 100,000 1000 1000 1000 1000 1000 662 0 1000 100,000 10,000 10,000 10,000 10,000 1000 1000 1000 664 0 0 100 1000 10,000 10,000 1000 1000 100 100 665 0 1000 100,000 100,000 100,000 100,000 100,000 10,000 10,000 10,000 682 0 100 100,000 100,000 100,000 100,000 10,000 x x 1000 684 x 0 10,000 10,000 10,000 10,000 1000 100 x 100 730 0 0 1000 1000 1000 1000 1000 1000 735 0 0 1000 10,000 10,000 10,000 1000 100 737 0 0 1000 10000 10000 1000 1000 1000 742 0 0 100,000 10,000 10,000 1000 1000 x 787 0 0 10,000 100,000 10,000 10,000 1000 1000 789 0 0 100,000 x x x x x

S8 Table S3. Cont. Mouse Number PreImmune Priming 1. Boost 2. Boost 1 month 2 month 3 month 4/5 month 6/7 month Final Weeks after Immunization 0 1 3 7 11 15 19 23/27 31/35 38 Age of Mice (Weeks) 10 11 13 27 21 25 29 33/37 41/45 48 790 0 0 100,000 100,000 100,000 10,000 10,000 1000 798 0 0 100,000 100,000 100,000 100,000 10,000 10,000 804 0 0 1000 100,000 100,000 100,000 10,000 10,000 807 0 0 1000 10,000 10,000 1000 1000 1000 885 0 0 10,000 10,000 10,000 1000 1000 887 0 0 10,000 10,000 100,000 10,000 10,000 952 0 0 10,000 10,000 10,000 10,000 1000 963 0 0 100,000 100,000 100,000 10,000 10,000 965 0 0 1000 1000 1000 100 100 973 0 0 1000 10,000 10,000 10,000 1000 974 0 0 1000 1000 10000 1000 1000 982 0 0 10,000 10,000 10,000 10,000 1000 966 x x x x x x x 1029 0 0 10000 x x x x Total number of mice n = 39 n = 39 n = 39 n = 37 n = 32 n = 37 n = 36 n = 26 n = 17 n = 20 Total number of mice with IR n = 5 n = 17 n = 39 n = 37 n = 32 n = 37 n = 35 n = 26 n = 16 n = 20 [%] of mice with IR 12.8% 43.6% 100% 100% 100% 100% 97.2% 100% 94.1% 100%

S9 Table S4. IgG 1/2a/2b/2c titers of mice immunized with Tau 199-208 [ps202/pt205], mo = months after the 2. boost. IgG1 IgG2a IgG2b IgG2c Tau 199-208 [ps202/pt205] Mouse Number 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 306 10,000 10,000 1000 1000 1000 100 0 0 10,000 10,000 1000 100 10,000 1000 1000 100 309 100,000 10,000 100 1000 1000 100 0 100 100 0 0 100 0 0 0 0 312 100,000 100,00 1000 100 0 0 0 0 1000 100 100 0 100 0 0 0 316 100,000 1000 100 100 100 0 0 0 1000 100 1000 100 1000 100 1000 100 320 10,000 10,000 1000 1000 0 0 0 0 1000 1000 1000 100 100 0 0 0 360 100,000 100,000 10,000 10,000 10,000 10,000 1000 1000 1000 100 100 100 100 0 0 0 362 1000 1000 100 100 0 0 0 0 0 0 100 0 0 0 0 0 363 10,000 1000 1000 100 0 0 0 0 100 100 100 0 100 100 100 0 364 100,000 10,000 1000 1000 100 100 0 0 100 100 1000 0 100 1000 100 0 558 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 627 10,000 1000 100 0 100 0 0 0 10,000 1000 100 100 1000 100 100 100 628 10,000 10,000 1000 100 0 0 0 0 100 1000 100 100 100 100 100 0 mean value 46000 13667 1367 1208 1025 858 83 92 2033 1125 383 58 1050 218 200 25

S10 Table S5. IgG 1/2a/2b/2c titers of mice immunized with Tau 209-217 [pt212/ps214], mo = months after the 2. boost. IgG1 IgG2a IgG2b IgG2c Tau 209-217 [pt212/ps214] Mouse Number 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo Final #289 10,000 1000 100 100 100 100 0 0 1000 1000 1000 100 100 1000 100 100 #291 10,000 0 100 0 100 0 100 100 1000 100 100 100 1000 0 100 0 #295 100,000 10,000 1000 100 100 0 1000 1000 100 0 1000 1000 1000 100 #390 10,000 1000 0 0 1000 100 0 0 100 0 0 0 0 0 0 0 #391 100 100 1000 0 0 0 100 0 100 0 0 0 0 0 0 0 #392 10,000 10,000 1000 100 1000 1000 1000 100 100 0 0 0 0 0 0 0 #394 1000 1000 100 0 0 100 0 0 0 100 0 0 0 100 100 0 #498 100,000 10,000 1000 1000 10,000 10,000 1000 1000 1000 100 100 100 100 0 0 0 #499 10,000 1000 100 100 1000 100 0 0 10,000 1000 1000 1000 10,000 1000 1000 100 #500 100,000 10,000 1000 1000 0 100 0 0 100 100 100 0 0 0 0 0 #537 100,000 10,000 10,000 1000 0 0 0 0 1000 1000 1000 100 100 100 100 0 #547 10,000 10,000 1000 1000 0 0 0 0 1000 0 1000 100 100 0 0 0 mean value 38425 5342 1367 391 1108 967 183 109 1367 367 367 125 1033 267 200 25

S11 Table S6. IgG 1/2a/2b/2c titers of mice immunized with Tau 229-237 [pt231/ps235], mo = months after the 2. boost. IgG1 IgG2a IgG2b IgG2c Tau 229-237 [pt231/ps235] Mouse Number 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo final 2. boost 2 mo 5 mo Final #275 10,000 10,000 1000 100 0 0 0 0 1000 1000 100 100 100 0 0 0 #282 10,000 1000 100 0 1000 100 0 0 100 0 0 0 100 0 0 0 #375 100,000 10,000 1000 100 1000 100 0 0 1000 100 100 0 100 100 0 0 #383 10,000 100 100 0 100 0 0 0 100 100 0 0 100 0 0 0 #424 100,000 100,000 10,000 1000 100 100 0 0 10,000 1000 1000 1000 10,000 1000 1000 100 #451 10,000 10,000 1000 0 0 100 0 0 1000 0 0 100 100 0 100 100 #452 100,000 1000 100 1000 1000 0 0 0 10,000 0 0 1000 10000 0 0 100 #455 100,000 0 10,000 1000 0 0 100 0 1000 1000 100 100 100 1000 1000 100 #456 100,000 1000 1000 100 1000 100 100 0 100,000 10,000 10,000 1000 100,000 10,000 10,000 1000 #481 10,000 10,000 100 1000 0 100 0 0 1000 10,000 100 100 1000 1000 100 0 #506 10,000 1000 1000 100 0 0 0 100 100 0 0 0 100 0 0 0 #511 100,000 1000 1000 100 100 0 0 0 10,000 0 1000 100 10,000 0 100 0 mean value 55000 12092 2200 375 358 50 17 8 11275 1933 1033 292 10975 1092 1025 117